Nomination Committee’s proposal for election of Board members 2022

The Nomination Committee of Boule Diagnostics AB has decided to propose to the Annual General Meeting 2022 (AGM) that the number of Board members shall be five, including the Chair. The Nomination Committee proposes the election of Yvonne Mårtensson as the Chairwoman of the Board and the re-election of Karin Dahllöf, Thomas Eklund, Torben Jørgensen and Jon Risfeldt as Board members. Charlotta Falvin and Peter Ehrenheim have declined re-election.

Yvonne Mårtensson has extensive experience from leading positions in international sales and marketing, primarily in medical equipment and diagnostics. She has successfully, in her role as CEO, taken CellaVision AB from a start-up to a global and fast-growing listed company. In addition, Yvonne has up until recently been the Chairwoman of the Board of Elos Medtech and is a Board member of XVIVO Perfusion. Yvonne was born in 1953 and has a Master of Science, Industrial Management at Institute of Technology, Linköping University.

More detailed information about the proposed Board members are available at the Company’s website.

The Nomination Committee’s proposals to the AGM 2022 in full and their motivated account will, at the latest, be disclosed together with the notice convening the Annual General Meeting as it is issued.

For more information, please contact:
Ulf Hedlundh, Chairman of the Nomination Committee,, phone +46 (0)8-440 37 70
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CET on February 11, 2022.

Nomination Committee’s proposal for election of Board members of Boule Diagnostics AB 220211

  • Subscribe to our news